Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VUM02 Injection in Idiopathic Pulmonary Fibrosis
NCT06230822Phase 1Completed
- Sponsor
- Wuhan Optics Valley Zhongyuan Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VUM02 in idiopathic pulmonary fibrosis (IPF), sponsored by Wuhan Optics Valley Zhongyuan Pharmaceutical. Primary endpoints: Incidence and severity of cell therapy-related adverse events at 28 days and Maximum tolerated dose at 28 days. Started Mar 2024; status: completed.
02
Drugs
VUM02
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06230822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06230822.